ReviewCureus2025
Role of Sodium-Glucose Transport Protein 2 (SGLT2) Inhibitors in Preventing Cardiac Surgery-Associated Acute Kidney Injury: A Scoping Review.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiac surgery-associated acute kidney injury (CSA-AKI) is a frequent and serious complication associated with increased morbidity, mortality, and healthcare costs. Sodium-glucose co-transporter 2 inhibitors (SGLT2i), including dapagliflozin and empagliflozin, have shown renoprotective benefits in chronic settings, but their perioperative role in CSA-AKI prevention is not well defined. This study was to map the current literature on the use of SGLT2 inhibitors such as empagliflozin and dapagliflozin for the prevention of CSA-AKI, identify evidence gaps, and inform future research directions. A scoping review was conducted using PubMed, Ovid (MEDLINE/Embase), Cochrane Library, and trial registries from January 2010 to May 2025. Eligible studies included adult cardiac surgery patients receiving SGLT2i therapy in the perioperative period. Data were extracted on study design, SGLT2i agent, timing, AKI definitions, outcomes, and safety reporting. Seven studies met the inclusion criteria, and one early-terminated trial met the inclusion criteria. The terminated study halted recruitment after achieving its predefined outcome and transitioned into a larger multicentre trial. Empagliflozin was the most frequently studied agent, with dapagliflozin included in a smaller subset. Findings suggest a lower incidence of CSA-AKI in patients receiving SGLT2i compared to controls; however, heterogeneity in study design, small sample sizes, and inconsistent safety reporting limit the strength of conclusions. Three ongoing randomized controlled trials were also identified, reflecting growing interest in this therapeutic strategy. Early data suggest that SGLT2 inhibitors may offer renoprotective effects in the cardiac surgical population. Evidence specific to dapagliflozin remains limited. Larger, high-quality RCTs are needed to determine efficacy, safety, and the optimal timing and perioperative use of SGLT2i to prevent CSA-AKI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.